Paul L. Feldman, PhD from Discovery and Translational Medicine Intarcia Therapeutics, Inc. will present the talk titled, "Application of The Intarcia Medici Drug Delivery System for Long Acting HIV Prevention for Global Health".
This seminar is co-sponsored by the School of Pharmacy and the School of Chemistry.
Abstract: The current rate of decrease of HIV infections in Africa is not enough to offset the rapidly growing population and without cost effective and highly efficacious HIV pre-exposure prophylaxis (PrEP) treatments, the absolute number of people infected with HIV will ultimately rise. Anti-retroviral therapy has been demonstrated to be highly effective for PrEP; however, adherence to drug therapy has been shown to be essential to achieve optimal efficacy. Intarcia’s Medici Drug Delivery SystemTM is comprised of an implantable osmotic mini-pump, a proprietary formulation that stabilizes drug assets for an extended period of time at body temperature, and efficient mini-pump placement and removal tools. Intarcia, in collaboration with the Bill and Melinda Gates Foundation, seeks to develop a one-year implant using its Medici Drug Delivery SystemTM containing a highly effective HIV PrEP treatment for use in high-risk, uninfected people in Sub-Saharan Africa. A summary of the technology and progress towards this HIV PrEP goal will be described.
Tuesday, February 5 at 12:00 p.m. to 1:00 p.m.